Overview

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Status:
Recruiting
Trial end date:
2024-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this extension study is to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study. The main objective is to assess brolucizumab's potential for long durability up to 20 weeks. All eligible participants will be treated with brolucizumab regardless of their treatment in the TALON study. The study period is 56 weeks including post-treatment follow-up.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals